About Technology Issues FAQ

Links

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.